Investment opportunity · Accredited investors
AI clinical decision support that physicians review, edit and approve
Tachyra reviews a patient’s full history, medications and lab trends before the visit. The physician makes every decision.
Join the investor waitlistThe problem
Physicians miss diagnoses and medication risks because no one has time to see the whole patient
795,000
Americans die or are permanently disabled each year from diagnostic error
62.5%
accuracy for an individual physician on standard cases, rising to 85.6% with collaborative review
125,000
deaths a year tied to medication non-adherence, plus $100–300B in avoidable costs
Sources: Newman-Toker et al., BMJ Quality & Safety, 2024 · Barnett et al., JAMA Network Open, 2019 · CDC and pharmacy literature on non-adherence
The solution
Tachyra reviews the whole patient before the visit; the physician makes every decision
1
Patient intake
Symptoms, history, medications and lab results gathered before the visit
2
AI review
Ranked differential, full medication-interaction check, personal baseline trends and treatment options
3
Physician decides
Reviews, edits and approves every recommendation. Tachyra never diagnoses or prescribes
4
Audit trail
Every approval, edit and override is logged, supporting quality review and liability defense
Sold as B2B software to independent physicians, group practices and health systems
Why physicians buy
It fits inside the EHR they already use and gives them back their time
~146 hrs
of chart review saved per physician per year, worth about $18,500 of physician time
Planning estimate: half of the ~6.5 minutes of chart review per primary-care visit. To be measured in pilots.
EHR integration
Works with the systems independent practices run today, such as Tebra, rather than replacing them
Pays for itself
Estimated time value exceeds the annual price of every tier through Growth ($17,988 a year)
Defensible record
A contemporaneous log of the reasoning behind each AI-assisted decision
Built today
Phase one is done: a working model and a plan to show investors
Live working prototype
- Symptom-to-medication correlation
- Beers Criteria polypharmacy assessment for older patients
- Therapeutic duplication and patient-specific dose flags
- Excipient and allergen checking
- FDA drug data integration (openFDA)
- Physician review screen with full audit trail
~100
physicians have applied to work with Tachyra
Next proof point
An unpaid, structured physician evaluation of the prototype, led by our Medical Director
Developed using an AI-first approach, with the leadership team accountable for every area
Market
464,000 U.S. private-practice physicians are our first market
TAM
$9.7B
Global AI-in-diagnostics market by 2033, from $2.0B in 2025 (21.7% CAGR)
SAM
~$1.1B
North America in 2025 (~55% of global), growing ~21.7% a year
SOM · YEAR 5
~$144M
~12,000 physicians, 2.6% of our target segment, at ~$12,000 a year each
Sources: Grand View Research, 2026 · AMA Physician Practice Benchmark Survey · SAM growth assumes North America holds its share of the global market · SOM is Tachyra’s own bottoms-up model
Business model
Recurring subscriptions priced by panel size, about $1–2 per patient a month
| Tier | Active patients | Monthly | Per patient |
|---|---|---|---|
| Founding Physician | Up to 300 | $149 | 6-month intro |
| Starter | Up to 300 | $549 | ~$1.83 |
| Standard | 301–750 | $999 | ~$1.33 |
| Growth | 751–1,500 | $1,499 | ~$1.00 |
| Large panel | 1,500+ | ~$2,499 | ~$0.83 |
| Health systems | Enterprise | Custom | — |
A full Growth-tier month for 1,500 patients costs less than one $160 self-pay office visit. Introductory pilot-stage pricing; willingness to pay will be validated with pilot physicians.
Competition
Others know the literature or one data source; Tachyra knows the patient
| Company | Per-patient differential | Full-regimen drug check | Personal lab baselines |
|---|---|---|---|
| Tachyra | Yes | Yes | Yes |
| Glass Health | Yes | No | No |
| Isabel Healthcare | Yes, on request | No | No |
| OpenEvidence, Doximity | No, literature Q&A | No | No |
| Quest, LabCorp, CVS | No | No | Own data only |
| Epic, Oracle Health | Building native AI | Partial | Not announced |
Based on public product information as of 2026.
Financial projection
Breakeven projected in year three
| Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | |
|---|---|---|---|---|---|
| Revenue | $0.24M | $4.95M | $31.9M | $92.0M | $191.0M |
| Gross margin | (36%) | 65% | 78% | 81% | 81% |
| EBITDA | ($5.9M) | ($9.3M) | $6.4M | $47.1M | $115.6M |
Illustrative planning estimates pending pilot validation; not a guarantee of future performance.
The opportunity
Raising $6 million to take Tachyra through clinical validation
· discount Set in the offering documents.
Use of proceeds
Draft terms, subject to the lead investor and securities counsel. A Series A of $15M–$25M is planned once pilot data exists.
Leadership
A leadership team in place, with key seats being filled
Barry Michaels, DC, MPA
Founder & Interim CEO
More than 50 years creating and running businesses in healthcare, aviation, publishing and real estate, including The Corporate Experts, which has formed more than 1,500 Nevada entities. Author of The Natural Therapies Handbook healthcare series.
Henri A. Ward
Chief Operating Officer
Healthcare and SaaS operator. Formerly General Manager of Fiserv’s healthcare vertical, Head of Product Management at Equifax, Global VP at Verint Systems and Director of Product Management at McKesson.
Patrick Turley
Chief Financial Officer
Finance executive with 20+ years building FP&A, treasury and board reporting at SaaS and cloud companies. Formerly CFO of Rev.io and SVP of Finance & Operations at itopia, where he helped scale revenue 4x and closed $18M in financing; 14 years at Citrix Systems. MBA, Nova Southeastern University.
Annie Casta, MD, FAAFP
Medical Director & VP of Clinical Affairs
Board-certified family physician, fellowship-trained in sports medicine and licensed in 46 states. National medical director experience leading multi-state physician teams; formerly with Teladoc Health.
Dhanashree Dorage
VP of Engineering
Software and cloud engineer with 10+ years across AWS, Microsoft Azure and Google Cloud. Led DevOps teams at Perficient, served as technical lead at Toyoda Gosei and has built AI-assisted web and mobile products. MS in Computer Science, Purdue University.
In active recruitment: Chief Medical Officer, Chief Technology Officer, General Counsel and VP of Sales
Milestones
What this round buys: proof physicians can show
Months 1–3
Close this round. Complete the physician evaluation. Pursue non-dilutive funding, including BARDA DRIVe.
Months 3–9
EHR-integrated platform build. Sign pilot practices. Retrospective validation. Begin FDA pre-submission dialogue.
Months 9–15
Commercial launch in one or two markets. Prospective pilot study measuring accuracy and time saved.
Months 15–24
Raise the Series A on pilot data. Expand to group practices and begin health-system talks.
WorldsSmartestPhysician.com
Help us give every physician a second set of eyes
Barry Michaels, DC, MPA — Founder & Interim CEO
info@tachyradiagnostics.com · tachyradiagnostics.com
Join the investor waitlistThis page is for information only and is not an offer to sell or a solicitation of an offer to buy any security. Any offering will be made only through definitive offering documents under Rule 506(c) to accredited investors whose status has been verified. Projections are illustrative and not guarantees of future results.